FDMT
4D Molecular Therapeutics Inc
13.70$
-1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
4D Molecular Therapeutics Inc (FDMT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -70 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.2 | -3.2 | -4.9 | -4.9 | -8.6 | -8.6 | -11 | -8.7 | -14 | -6.2 | -13 | -17 | -15 | -16 | -16 | -22 | -24 | -20 | -21 | -22 | -28 | -22 | -1.2 | -25 | -29 | -30 | -29 | -46 | -48 | -43 | -46 | 29 | -68 | -70 | -156 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.7 | 0.7 | 0.8 | 1.9 | 0.8 | 0.8 | 0.9 | 1.4 | 1.4 | 1.4 | 1.4 | 1.5 | 1.6 | 1.6 | 1.7 | 1.8 | 1.8 | 1.9 | 2.0 | 2.0 | 2.1 | 0.5 | 6.5 | |
| 0.2 | 0.2 | 0.5 | 0.5 | 0.7 | 0.7 | 1.1 | 1.0 | 1.1 | 1.0 | 1.1 | 1.7 | 2.3 | 3.8 | 3.9 | 3.7 | 3.9 | 4.3 | 4.5 | 4.3 | 4.2 | 5.0 | 4.6 | 5.9 | 6.0 | 6.1 | 6.5 | 7.6 | 7.0 | 5.0 | 4.5 | 5.6 | 4.5 | 5.9 | 20 | |
| – | – | – | – | 0.7 | 0.7 | 6.2 | 1.1 | 1.1 | 1.0 | – | 1.8 | 2.4 | 3.8 | 4.0 | 4.5 | 3.9 | 4.3 | 4.5 | 4.3 | 4.2 | 5.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.6 | -0.6 | 0.3 | 0.3 | 0.0 | 0.0 | -0.6 | 3.4 | -2.2 | 7.6 | -2.8 | 0.9 | -2.2 | -13 | 1.8 | -3.1 | -2.5 | 2.5 | -1.0 | -0.4 | -4.5 | 1.4 | 3.1 | 0.7 | -3.5 | -0.7 | 8.5 | -3.7 | -7.2 | 5.6 | 5.0 | 2.8 | -4.8 | -3.6 | -0.6 | |
| 0.0 | 0.0 | 0.2 | 0.2 | 0.8 | 0.8 | 1.1 | 0.5 | 0.7 | 0.1 | 0.3 | 0.5 | 0.6 | 0.7 | 2.6 | 5.1 | 6.4 | 2.1 | 2.0 | 1.1 | 1.0 | 0.8 | 0.4 | 0.5 | 0.7 | 0.3 | 1.8 | 0.9 | 0.6 | 0.1 | 0.1 | 0.6 | 0.0 | 0.1 | 0.8 | |
| 0.0 | 0.0 | -0.2 | -0.2 | -0.8 | -0.8 | -1.1 | -0.5 | -0.7 | -0.1 | 0.3 | -0.5 | -0.6 | -0.7 | -139 | -32 | -54 | 57 | 15 | -36 | 43 | 49 | 30 | -6.7 | -263 | -74 | 27 | 7.1 | 32 | -14 | 18 | -129 | 69 | 26 | -17 | |
| – | – | – | – | – | – | – | – | – | – | – | – | -0.8 | -0.1 | – | 116 | -0.2 | -0.1 | 0.8 | -0.9 | 11 | 128 | – | – | – | – | – | – | – | – | – | 7.5 | – | – | – | |
| 0.0 | 0.0 | 42 | 42 | 0.0 | 0.0 | -1.5 | -0.7 | -0.4 | 72 | 0.9 | 206 | -0.8 | 0.8 | 2.0 | 116 | 0.6 | -0.1 | 0.5 | 2.0 | 11 | 131 | 11 | 4.8 | 319 | 17 | 0.6 | 0.6 | 0.0 | 0.9 | 0.1 | 112 | 11 | 42 | 166 | |
| -3.2 | -3.2 | 37 | 37 | -9.4 | -9.4 | -13 | -9.8 | -50 | 66 | -12 | 188 | -17 | -16 | -153 | 62 | -77 | 38 | -5.2 | -56 | 26 | 158 | 39 | -27 | 26 | -87 | -1.5 | -38 | -16 | -64 | -29 | 12 | 12 | -2.1 | -6.8 | |
| -3.2 | -3.2 | -5.1 | -5.1 | -9.4 | -9.4 | -12 | -9.2 | -15 | -6.3 | -13 | -18 | -16 | -17 | -18 | -27 | -30 | -22 | -23 | -23 | -29 | -23 | -1.6 | -25 | -30 | -31 | -31 | -47 | -48 | -43 | -46 | 28 | -68 | -70 | -157 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.